Literature DB >> 25916947

Salivary duct carcinoma: Treatment, outcomes, and patterns of failure.

Meredith L Johnston1, Shao Hui Huang1, John N Waldron1, Eshetu G Atenafu2, Kelvin Chan3, Bernard J Cummings1, Ralph W Gilbert4, David Goldstein4, Patrick J Gullane4, Jonathan C Irish4, Bayardo Perez-Ordonez5, Ilan Weinreb5, Andrew Bayley1, John Cho1, Laura A Dawson1, Andrew Hope1, Jolie Ringash1, Ian J Witterick4, Brian O'Sullivan1, John Kim1.   

Abstract

BACKGROUND: Salivary duct carcinoma is rare, with distinct morphology and behavior. We reviewed our institutional experience with salivary duct carcinoma, aiming to characterize clinical behavior and treatment outcomes.
METHODS: All salivary duct carcinomas treated curatively between 1999 and 2010 were reviewed. Overall survival (OS), locoregional control, distant control, and patterns of failure were analyzed. Multivariate analysis identified predictors of OS.
RESULTS: Fifty-four patients with salivary duct carcinoma (parotid gland = 49; submandibular gland = 5) were included in the analysis. Fifty-three patients underwent primary surgery, and 48 (89%) received postoperative radiotherapy (RT; median dose = 60 Gy). Median follow-up was 5.7 years. The 5-year OS, locoregional control, and distant control were 43%, 70%, and 48%, respectively. Nine local (6 involving facial nerve), 10 regional, and 28 distant failures were identified. Multiple pathologic involved lymph nodes (pN2b/N2c) predicted reduced OS (hazard ratio [HR] = 3.6; p = .02).
CONCLUSION: Distant recurrence is common. Presence of pN2b/N2c disease is associated with reduced OS. Local recurrence frequently involves the facial nerves.
© 2015 Wiley Periodicals, Inc. Head Neck 38: E820-E826, 2016. © 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  head and neck; pattern of failure; radiotherapy; salivary duct carcinoma; surgery

Mesh:

Year:  2015        PMID: 25916947     DOI: 10.1002/hed.24107

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  28 in total

1.  PD-L1 expression by immunohistochemistry in salivary duct carcinoma.

Authors:  Ameer Hamza; Dianna Roberts; Shirley Su; Randal S Weber; Diana Bell; Renata Ferrarotto
Journal:  Ann Diagn Pathol       Date:  2019-04-03       Impact factor: 2.090

2.  Impact of postoperative radiotherapy and HER2/new overexpression in salivary duct carcinoma : A monocentric clinicopathologic analysis.

Authors:  Marlen Haderlein; Claudia Scherl; Sabine Semrau; Sebastian Lettmaier; Markus Hecht; Ramona Erber; Heinrich Iro; Rainer Fietkau; Abbas Agaimy
Journal:  Strahlenther Onkol       Date:  2017-08-21       Impact factor: 3.621

3.  Increased ERBB2 Gene Copy Numbers Reveal a Subset of Salivary Duct Carcinomas with High Densities of Tumor Infiltrating Lymphocytes and PD-L1 Expression.

Authors:  Kyriakos Chatzopoulos; Andrea R Collins; Sotiris Sotiriou; Michael G Keeney; Daniel W Visscher; Michael Rivera; David J Schembri-Wismayer; Jean E Lewis; Patricia T Greipp; William R Sukov; Ashish V Chintakuntlawar; Katharine A Price; Joaquin J Garcia
Journal:  Head Neck Pathol       Date:  2020-04-29

4.  Salivary duct carcinoma: evaluation of treatment and outcome in a tertiary referral institute.

Authors:  Ann-Jean C C Beck; Peter J F M Lohuis; Abrahim Al-Mamgani; Laura A Smit; Willem M C Klop
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-05-21       Impact factor: 2.503

5.  Salivary duct carcinoma treated with cetuximab-based targeted therapy: A case report.

Authors:  Kenta Kawahara; Akimitsu Hiraki; Ryoji Yoshida; Hidetaka Arita; Yuichiro Matsuoka; Toshio Yamashita; Kan-Ichi Koga; Masashi Nagata; Akiyuki Hirosue; Daiki Fukuma; Hideki Nakayama
Journal:  Mol Clin Oncol       Date:  2017-04-21

6.  Oncological outcomes of patients with salivary gland cancer treated with surgery and postoperative intensity-modulated radiotherapy: a retrospective cohort study.

Authors:  Shoumei Zang; Meiqin Chen; Huijie Huang; Xinli Zhu; Xinke Li; Danfang Yan; Senxiang Yan
Journal:  Quant Imaging Med Surg       Date:  2022-05

Review 7.  Molecular Pathology and Biomarkers.

Authors:  Patrick K Ha; Göran Stenman
Journal:  Adv Otorhinolaryngol       Date:  2016-04-12

Review 8.  Salivary duct carcinoma: An aggressive salivary gland malignancy with opportunities for targeted therapy.

Authors:  Nicole C Schmitt; Hyunseok Kang; Arun Sharma
Journal:  Oral Oncol       Date:  2017-09-21       Impact factor: 5.337

9.  Excellent Response With Alpelisib and Bicalutamide for Advanced Salivary Duct Carcinoma With PIK3CA Mutation and High Androgen Receptor Expression-A Case Report.

Authors:  Hardik Sheth; Prashant Kumar; Aditya Shreenivas; Janani Sambath; Ramya Pragya; Chetan Madre; Nevitha Athikari; Hemant Khandare; Vishal Peshattiwar; Rajan Datar; Sewanti Limaye
Journal:  JCO Precis Oncol       Date:  2021-05-03

10.  Patterns of treatment failure in salivary gland cancers.

Authors:  Mateusz Szewczyk; Paweł Golusiński; Jakub Pazdrowski; Piotr Pieńkowski; Sławomir Marszałek; Jacek Sygut; Wojciech Golusiński
Journal:  Rep Pract Oncol Radiother       Date:  2018-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.